LIXTE Biotechnology Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative)													12 Months Ended
Commitments and Contingencies (Details Narrative)	Nov. 03, 2018 USD ($)	Sep. 12, 2018 USD ($)	Aug. 20, 2018 USD ($)	Jun. 14, 2018 USD ($)	Apr. 05, 2018 USD ($)	Apr. 05, 2018 EUR (€)	Apr. 02, 2018	Mar. 22, 2018 USD ($)	Jul. 09, 2017 USD ($)	Jun. 14, 2017 USD ($)	Sep. 14, 2015 USD ($)	Dec. 24, 2013 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)
Research and development costs													$ 820,906	$ 40,703
Unamortized balance of the retainer payment classified as a non-current asset														2,293
Accreted charges														25,000
Reversal of accreted charges														25,000
NDA Consulting Corp [Member]
Agreement term												1 year
Consulting and advisory fee												$ 4,000	16,000	16,000
Clinical Trial Research Agreement [Member]
Research and development costs													45,093
Clinical Trial Research Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Research and development costs													45,093	0
Collaboration Agreement [Member]
Research and development costs													87,471
Collaboration Agreement [Member] \| BioPharmaWorks LLC [Member]
Research and development costs													100,000	10,000
Consulting and advisory fee											$ 10,000
Collaboration Agreement [Member] \| Grupo Espanol de Investigacion en Sarcomas [Member]
Research and development costs													87,471
Clinical Trial Agreement [Member]
Aggregate commitments expected													$ 5,000,000
Aggregate commitments expected, description													The Company's aggregate commitments pursuant to these clinical trial agreements, less amounts previously incurred to date under these agreements, totaled approximately $5,000,000 as of December 31, 2019, which are expected to be incurred over the next five years through 2024.
Work Order Agreement [Member]
Research and development costs													$ 63,492
Work Order Agreement [Member] \| Theradex Systems, Inc [Member]
Research and development costs		$ 954,000											51,586	11,906
Payment expected dividend for pass-through costs, description		The clinical trial is expected to be completed over a period of two years, with final analysis and reporting expected within three years. Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.
Material Transfer Agreement [Member] \| INSERM [Member] \| Development Milestones [Member] \| Maximum [Member]
Milestone payments								$ 1,750,000
Material Transfer Agreement [Member] \| INSERM [Member] \| Commercial Milestones [Member] \| Maximum [Member]
Milestone payments								$ 6,500,000
Consulting Agreement with Liberi Life Consultancy BV [Member]
Agreement term							2 years
Payment of a fixed, one-time retainer one time retainer					$ 18,348
Net payments of sales of products or licensing activities, percentage					2.50%	2.50%
Consulting Agreement with Liberi Life Consultancy BV [Member] \| EURO [Member]
Payment of a fixed, one-time retainer one time retainer \| €						€ 15,000
Consulting Agreement [Member]
Amortizing the retainer payment													9,174	6,881
Unamortized balance of the retainer payment													$ 2,294	11,468
Unamortized balance of the retainer payment classified as a current asset														9,175
Unamortized balance of the retainer payment classified as a non-current asset														2,293
Royalties description													The Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products, subject to reduction to 2% under certain circumstances, on a quarterly basis, with a minimum royalty payment of $50,000 in the first four years after sales commence, and $100,000 in year five and each year thereafter, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the License Agreement.
Exclusive License Agreement [Member]
Amount charges to operations													$ 80,669	$ 0
Exclusive License Agreement [Member] \| First Four Years [Member]
Minimum payments for royalties													50,000
Exclusive License Agreement [Member] \| Five Years and Thereafter [Member]
Minimum payments for royalties													$ 100,000
Exclusive License Agreement [Member] \| Moffitt Cancer Center and Research Institute Hospital Inc [Member]
Non-refundable license issue fee			$ 25,000
Clinical trial analysis expected term			2 years
Clinical trial final analysis expected term			3 years
Annual license maintenance fee			$ 25,000
Payments on non-refundable milestone			$ 1,897,000
Percentage of milestone			40.00%
Materials Cooperative Research and Development Agreement [Member]
Funds provide for use in acquiring technical, statistical and administrative support for research activities										$ 100,000
Materials Cooperative Research and Development Agreement [Member] \| First Installment [Member]
Paid two equal installments									$ 50,000
Materials Cooperative Research and Development Agreement [Member] \| Second Installment [Member]
Paid two equal installments				$ 50,000
Cancellation of installment, amount	$ 50,000